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Abstract
Following an application from Suomen Terveysravinto Oy, submitted for authorisation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Finland, the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on
the scientiﬁc substantiation of a health claim related to curcumin and normal functioning of joints. The
food that is proposed as the subject of the health claim is curcumin. The Panel considers that
curcumin is sufﬁciently characterised. The claimed effect proposed by the applicant is ‘normal
functioning of joints by reducing the biomarkers of inﬂammation’. The target population proposed by
the applicant is the general population. Upon a request from EFSA to clarify whether the claimed effect
is related to the normal function of joints or rather to the reduction of inﬂammation, the applicant did
not address this issue in the reply. The Panel assumes that the claimed effect refers to the
maintenance of joint function. The Panel considers that maintenance of joint function is a beneﬁcial
physiological effect. The Panel considers that no conclusions can be drawn from 15 human
intervention studies conducted in patients with osteoarthritis or rheumatoid arthritis and from one
study in obese subjects on serum cytokines for the scientiﬁc substantiation of the claim. In the
absence of evidence for an effect of curcumin on the normal function of joints in humans, the results
of the human studies on curcumin pharmacokinetics, safety and mechanistic studies, the animal
studies and the in vitro studies submitted by the applicant cannot be used as a source of data for the
scientiﬁc substantiation of the claim. The Panel concludes that a cause and effect relationship has not
been established between the consumption of curcumin and maintenance of joint function.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from Suomen Terveysravinto Oy, submitted for authorisation of a health
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Finland,
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientiﬁc substantiation of a health claim related to curcumin and normal functioning of joints.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications and the guidance on the
scientiﬁc requirements for health claims related to guidance on the scientiﬁc requirements for health
claims related to bone, joints, skin and oral health.
The food that is proposed as the subject of the health claim is curcumin. The Panel considers that
curcumin, which is the subject of the health claim, is sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘normal functioning of joints by reducing the
biomarkers of inﬂammation’. The target population proposed by the applicant is the general
population. Upon a request from the European Food Safety Authority (EFSA) to clarify whether the
claimed effect is related to the normal function of joints or rather to the reduction of inﬂammation, the
applicant did not address this issue in the reply. In the absence of clariﬁcation from the applicant and
taking into account the proposed wording for the claim, the Panel assumes that the claimed effect
refers to the maintenance of joint function. The Panel considers that maintenance of joint function is a
beneﬁcial physiological effect.
The applicant identiﬁed 16 human intervention studies on the effects of curcumin on ‘markers’ of joint
function as being pertinent to the claim. The Panel notes that 11 studies were performed in patients with
knee osteoarthritis, two were performed in patients with osteoarthritis and clinical manifestations in
many joints, and two were conducted in patients with rheumatoid arthritis. The Panel considers that no
conclusions can be drawn from these 15 human intervention studies conducted in patients with
osteoarthritis or rheumatoid arthritis for the scientiﬁc substantiation of the claim. Another human
intervention study conducted in obese subjects assessed the effects of curcumin in combination with
bioperine on 12 of serum cytokines; joint function was not assessed. The Panel considers that no
conclusions can be drawn from this study for the scientiﬁc substantiation of the claim.
The Panel considers that, in the absence of evidence for an effect of curcumin on the normal
function of joints in humans, the results of the human studies on curcumin pharmacokinetics, safety
and mechanistic studies (n = 15), the animal studies (n = 12) and the in vitro (n = 12) studies
submitted by the applicant cannot be used as a source of data for the scientiﬁc substantiation of the
claim. The Panel considers also that no conclusions can be drawn from 25 narrative reviews for the
scientiﬁc substantiation of the claim.
On the basis of the data presented, the Panel concludes that a cause and effect relationship has
not been established between the consumption of curcumin and maintenance of joint function.
Curcumin and normal functioning of joints
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with Article
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on
the scientiﬁc substantiation of a health claim related to: curcumin and normal functioning of joints.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of curcumin, a positive assessment of its safety, nor a decision on whether curcumin is, or is
not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
2.1.1.1. Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is curcumin. Curcumin is a
general product that is separated from turmeric (Curcuma longa L., Curcuma domestica). Turmeric is
comprised of a group of three curcuminoids: curcumin (diferuloylmethane), demethoxycurcumin and
bisdemethoxycurcumin, as well as volatile oils (tumerone, atlantone and zingiberone), sugars, proteins
and resins. Curcumin is a lipophilic polyphenol that is nearly insoluble in water but is quite stable in the
acidic pH of the stomach. It may make up 2–5% of the total spice in turmeric. Commercial curcumin
contains three major components: diferuloylmethane (82%), demethoxycurcumin (15%) and
bisdemethoxycurcumin (3%), together referred to as curcuminoids.
2.1.1.2. Health relationship as claimed by the applicant
According to the applicant, the claimed effect relates to: ‘normal functioning of joints by reducing the
biomarkers of inﬂammation. This helps to preserve the normal functioning and alleviate possible
inﬂammations in the joints and joint cartilage’. The outcome measures used to assess the relationship
between curcumin and normal functioning of joints were ‘standardized tools such as the WOMAC scale’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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2.1.1.3. Mechanism by which the food/constituent could exert the claimed effect as
proposed by the applicant
According to the applicant, curcumin acts as an antioxidant and reduces the biomarkers of
inﬂammation.
2.1.1.4. Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘curcumin contributes to the
normal functioning of joints’.
2.1.1.5. Speciﬁc conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is the general
population. At least 500 mg is recommended as an effective dose. Pregnant women should avoid
using curcumin.
2.1.2. Data provided by the applicant
Health claim application on consumption of curcumin and normal function of joints pursuant to
Article 13.5 of Regulation 1924/2006, presented in a common and structured format as outlined in the
Scientiﬁc and technical guidance for the preparation and presentation of applications for authorisation
of health claims.2
As outlined in the General guidance for stakeholders on health claim applications,3 it is the
responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientiﬁc requirements for health claims related to bone, joints, skin and oral health are
outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2012).
3. Assessment
3.1. Characterisation of the food/constituent
The food that is proposed by the applicant as the subject of the health claim is curcumin.
Curcumin, a hydrophobic polyphenol, is the principal constituent extracted from dried rhizomes of
C. longa L. (turmeric), synonym of C. domestica Valeton. It is also known as diferuloylmethane, with a
chemical formula (1E,6E)-1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, a molecular
formula C21H20O6, and a molecular weight of 368.39 g/mol.
Together with demethoxycurcumin and bis-demethoxycurcumin, curcumin belongs to the chemical
group of curcuminoids. Curcumin is obtained by solvent extraction of turmeric, i.e. the ground
rhizomes of natural strains of C. longa. In order to obtain a concentrated curcumin powder, the extract
is puriﬁed by crystallisation (EFSA ANS Panel, 2010).
Curcumin is used as a colouring agent by the food industry and it is known under food additive
E-code number E 100.
The Panel considers that curcumin, which is the subject of the health claim, is sufﬁciently
characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘normal functioning of joints by reducing the
biomarkers of inﬂammation’. The target population proposed by the applicant is the general population.
2 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Sj€odin A, Stern M, Tome D, Van Loveren H, Vinceti M, Willatts P, Martin A, Strain JJ, Heng L, Valtuena
Martınez S and Siani A, 2017. Scientiﬁc and technical guidance for the preparation and presentation of a health claim
application (Revision 2). EFSA Journal 2017;15(1):4680, 31 pp. https://doi.org/10.2903/j.efsa.2017.4680
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. General scientiﬁc guidance for stakeholders
on health claim applications. EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.2903/j.efsa.2016.4367
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Upon a request from EFSA to clarify whether the claimed effect is related to the normal function of
joints or rather to the reduction of inﬂammation, the applicant did not address this issue in the reply.
The applicant explained that the outcome measures used to assess the relationship between curcumin
and normal functioning of joints were standardised tools such as the WOMAC scale.
In the absence of clariﬁcation from the applicant and taking into account the proposed wording for
the claim, the Panel assumes that the claimed effect refers to the maintenance of joint function.
Possible outcomes related to joint function include mobility, stiffness and (dis)comfort (e.g. pain). For
example, validated protocols and procedures under well-deﬁned testing conditions using appropriate
goniometers have been used to assess the mobility of different joints (e.g. knee, ankle); validated
questionnaires could be used for the assessment of joint stiffness and (dis)comfort. For self-reported
outcome measures, adequate blinding of subjects is particularly important (EFSA NDA Panel, 2012).
The Panel considers that maintenance of joint function is a beneﬁcial physiological effect.
3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search with the use of the following key words: ‘curcumin,’
‘curcumin joints,’ ‘curcumin inﬂammation,’ and later, ‘curcumin osteoarthritis’. Details on the literature
searches were not provided. The Panel notes that no information was provided how the studies were
selected.
The applicant identiﬁed 16 human intervention studies on the effects of curcumin on ‘markers’ of
joint function as being pertinent to the claim. The Panel notes that 11 studies were performed in
patients with knee osteoarthritis (Chopra et al., 2004; Kuptniratsaikul et al., 2009, 2014; Belcaro et al.,
2010, 2014; Kertia et al., 2012; Pinsornsak and Niempoog, 2012; Madhu et al., 2013; Henrotin et al.,
2014; Nakagawa et al., 2014; Panahi et al., 2014), two were performed in patients with osteoarthritis
and clinical manifestations in many joints (Kulkarni et al., 1991; Appelboom et al., 2014), and two
were conducted in patients with rheumatoid arthritis (Deodhar et al., 1980; Chandran and Goel, 2012).
In order to explain why the results of these 15 human intervention studies conducted in patients
with osteoarthritis or rheumatoid arthritis could be extrapolated to the target population for the claim
(i.e. the general population), the applicant argued that biomarkers of inﬂammation are ‘connected’ to
joint health, and that the reduction in markers of inﬂammation shown in patients with osteoarthritis
has also been observed in vitro and in healthy subjects, so that the results obtained with curcumin in
patients with osteoarthritis could be extrapolated to the general population. The applicant also argued
that one study (Henrotin et al., 2014) showed that curcumin reduced serum concentrations of peptide
of the alpha-helical region of type II collagen (Coll2-1), which suggests that curcumin could reduce
cartilage matrix degradation, that this is supported by the in vitro observation that curcumin inhibits
matrix metalloproteinase-a (MMP-a) production by chondrocytes, and that this ‘ought to work similarly
with non-osteoarthritis population’.
The Panel considers that, as speciﬁed in EFSA’s guidance (EFSA NDA Panel, 2012), ‘the available
scientiﬁc evidence does not establish that results obtained in patients with osteoarthritis (degenerative
arthrosis) relating to the treatment of symptoms of this disease [. . .] can be extrapolated to the target
population for the claim (subjects without the disease). This is because normal cells and tissues are
genetically (gene expression) and functionally different from osteoarthritic cells and tissues, and
therefore may respond differently to interventions with exogenous substances. In addition, the
mechanisms involved in the onset and/or progression of osteoarthritis are largely unknown, so that it
cannot be established that an intervention which has an effect on the progression of the disease (in
patients with osteoarthritis), would also have an effect on its onset (subjects without the disease)”.
Also, “studies on subjects with arthritis of various origins (rheumatoid arthritis, [. . .]) and which relate
to the treatment of symptoms of the disease cannot be considered for the scientiﬁc substantiation of
health claims on joint function in the general population’.
The Panel considers that no conclusions can be drawn from these 15 human intervention studies
conducted in patients with osteoarthritis or rheumatoid arthritis for the scientiﬁc substantiation of the
claim targeted for the general population.
Another human intervention study (Ganjali et al., 2014) conducted in obese subjects assessed the
effects of curcumin in combination with bioperine on 12 serum cytokines; joint function was not
assessed. The Panel considers that no conclusions can be drawn from this study for the scientiﬁc
substantiation of the claim.
The Panel considers that, in the absence of evidence for an effect of curcumin on the normal
function of joints in humans, the results of the human studies on curcumin pharmacokinetics, safety
Curcumin and normal functioning of joints
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and mechanistic studies (n = 15), the animal studies (n = 12) and the in vitro (n = 12) studies
submitted by the applicant cannot be used as a source of data for the scientiﬁc substantiation of the
claim. The Panel considers also that no conclusions can be drawn from 25 narrative reviews for the
scientiﬁc substantiation of the claim.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of curcumin and maintenance of joint function.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• the food/constituent, curcumin, which is the subject of the health claim, is sufﬁciently
characterised.
• the claimed effect proposed by the applicant is ‘normal functioning of joints’. The target
population proposed by the applicant is the general population. Maintenance of joint function
is a beneﬁcial physiological effect.
• A cause and effect relationship has not been established between the consumption of
curcumin and maintenance of joint function.
Steps taken by EFSA
Health claim application on ‘curcumin’ and ‘normal functioning of joints’ pursuant to Article 13(5) of
Regulation (EC) No 1924/2006 (Claim serial No: 000856_0451_FI). Submitted by Suomen
Terveysravinto Oy, PL 146, 33101, Tampere, Finland.
1) This application was received by EFSA on 19/12/2016.
2) The scientiﬁc evaluation procedure started on 13/1/2017.
3) On 18/1/2017, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 11/2/2017 and was restarted on 21/2/2017, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
4) On 20/1/2017, EFSA received the applicant’s reply (which was made available to EFSA in
electronic format on 20/1/2017).
5) During its meeting on 4/4/2017, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to curcumin and normal
functioning of joints.
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